This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Accelrys Fast-tracks Scientific Innovation With Modeling And Simulation Software Release

Stocks in this article: ACCL

BRUSSELS, June 20, 2012 /PRNewswire/ -- Accelrys, Inc. (NASDAQ: ACCL), a leading scientific enterprise R&D software and services company, today announced the release of Accelrys Discovery Studio ® 3.5 modeling and simulation software during the company's European Science Symposium in Brussels. The latest release extends Discovery Studio's portfolio of small-molecule ligand design and market-leading biological simulation tools, including a new, validated ligand-profiling database for drug repurposing studies, new science to assess the development potential of putative biologics and many additional enhancements that help deliver a highly effective life sciences modeling and simulation environment.

To view the multimedia assets associated with this release, please click http://www.prnewswire.com/news-releases/accelrys-fast-tracks-scientific-innovation-with-modeling-and-simulation-software-release-159617375.html

New, validated science built upon active, ongoing partnerships is the keystone underlying the latest Discovery Studio 3.5 release. Discovery Studio's new ligand-profiling solution uses a spatial aggregation propensity algorithm and Developability Index licensed from the Massachusetts Institute of Technology ( MIT) and validated in collaboration with Novartis Pharma AG. Capabilities such as these provide important indicators of whether ligands and proteins will be good candidates for downstream development.

"The current economic squeeze on scientific resources across industries is counterbalanced by a continuing critical need for scientific innovation and excellence," said Senior Vice President and Chief Technology Officer Dr. Matt Hahn. "Deploying Discovery Studio modeling and simulation software on the scientifically aware Accelrys Enterprise Platform can help organizations meet the critical performance, cost and innovation goals that define today's increasingly information-driven R&D environments."

Discovery Studio 3.5 accelerates innovative modeling and simulation workflows by providing:

  • New science supporting small-molecule ligand design including a new ligand-profiling database for drug repurposing and side-effect studies; new in situ lead optimization and core-hopping tools for fragment-based drug design; and new activity cliffs and activity effects analysis based on Matched Molecular Pairs analysis
  • New science supporting biotherapeutics including new calculations for ranking protein-protein aggregation and improved capability to perform pH-dependent mutation energy (binding) calculations
  • Up-to-date Scientific Collections, enabling organizations to build, deploy, analyze and report on complex scientific data types using the Accelrys Enterprise Platform  
  • Updated partner ecosystem including support for the latest releases of CHARMm molecular simulation software and the MODELER program for comparative protein structure modeling
  • Enhanced usability, accessibility and visualization including enhanced generation of receptor-ligand interaction surfaces and improved display and rendering of 3D molecular objects

Discovery Studio provides comprehensive modeling and simulation capabilities for computational chemists, computational biologists and other scientists engaged in either small or large molecule life sciences R&D. The software speeds innovation, reduces costs, enhances productivity and improves outcomes through the automation and expert use of predictive science.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 18,053.71 +23.50 0.13%
S&P 500 2,088.77 +6.89 0.33%
NASDAQ 4,806.8590 +33.3870 0.70%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs